Search This Blog

Friday, March 6, 2026

Allarity $20 m non-convertible debt financing to support development of stenoparib

 

Allarity Therapeutics closes $20 million non-convertible debt financing with Streeterville Capital to support development of stenoparib

  • Financing is expected to extend Allarity Therapeutics' cash runway into mid-2028.
  • Proceeds will fund continued Phase 2 and pivotal development of ovarian cancer drug stenoparib.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)